Sign up online today & collaborate
or click here to find out more
Genticel is a step closer to prevent cancer caused by the human papillomavirus (HPV). The French biotech announced positive results of GTL002′s preclinical in vivo proof of concept, Genticel’s multivalent HPV therapeutic vaccine candidate based on the company’s versatile Vaxiclase platform.
Vaxiclase is a technology platform that can be used with many antigens in several indications. Last February, Genticel signed a first licensing agreement with the Serum Institute of India, the world’s largest producer of vaccine doses, to evaluate Vaxiclase to produce multivalent vaccines against Pertussis, the whooping cough disease. Genticel received up to €51M in upfront and milestones payments, plus royalties on sales.
For more click here